Ciphergen, Novartis Expand Compound Profiling Deal | GenomeWeb

SAN FRANCISCO, Nov. 5 - Ciphergen Biosystems said today it expanded an agreement with Novartis to conduct compound profiling for the pharmaceutical company.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.